Rajesh Dash1, Paul Kim1, Yuka Matsuura1, Fumiaki Ikeno1, Jennifer Lyons1, Xiaohu Ge1, Scott Metzler2, Ngan Huang1, Patricia Nguyen3, Joseph Wu1, 4, John Cooke1, Pilar Ruiz-Lozano2, Robert C. Robbins5, Michael V. McConnell1, Alan C. Yeung1, Phillip Harnish6, Phillip C. Yang1
1Medicine / Cardiovascular Medicine, Stanford University Medical Center, Stanford, CA, United States; 2Pediatrics, Lucille Packard Childrens Hospital, Stanford, CA, United States; 3Medicine / Cardiovascular Medicine, Palo Alto VA Medical Center, Stanford, CA, United States; 4Radiology, Stanford University Medical Center, Stanford, CA, United States; 5Cardiac Surgery, Stanford University Medical Center, Stanford, CA, United States; 6Eagle Vision Pharmaceutical Corporation, Downington, PA, United States
We delivered human amnion-derived mesenchymal stem cells (hAMSCs) intramyocardially and tracked in vivo survival using manganese-enhanced MRI (MEMRI). hAMSC therapy led to durable improvements cardiac function due to prolonged survival in vivo, which was confirmed by both MEMRI and co-localized signal from a HSV-tk PET reporter gene. Significant, persistent increases in ejection fraction, as well as reduced LV dilatation and scar volume were observed for up to 6 weeks after hAMSC therapy. Notably, MEMRI CNR increased over time in hAMSC-treated hearts, and immunohistochemistry confirmed the presence of hAMSCs with both human anti-mitochondrial and anti-nuclear antigen antibody staining.